1.Herbal Textual Research on Houttuyniae Herba in Famous Classical Formulas
Dan ZHAO ; Changgui YANG ; Chuanzhi KANG ; Chenghong XIAO ; Zhikun WU ; Hongliang MA ; Jiwen WANG ; Xiufu WAN ; Sheng WANG ; Zhilai ZHAN
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(8):250-259
This article systematically analyzes the historical evolution of the name, medicinal parts, origin, harvesting, processing and other aspects of Houttuyniae Herba(HH) by referring to the medical books, prescription books and other documents of the past dynasties, combined with the research materials related to modern and contemporary times, in order to provide a basis for the development of famous classical formulas containing this herb. In ancient literature, HH was often referred to as "Ji" and "Jicai", the name of "Ji" was first recorded in Mingyi Bielu during the Han and Wei dynasties, and the name of Yuxingcao was first seen in Lyuchanyan Bencao during the southern Song dynasty and has continued to this day. The origin of HH used throughout history is consistent, all of which are the whole herb or aboveground parts of Houttuynia cordata in Saururaceae family. HH recorded throughout history has a wide range of production areas, mostly self-produced self-marketing. In ancient times, fresh HH was often used as medicine by pounding its juice without involving any processing steps. Both fresh and dried products can be used as medicine, the fresh products uses the whole plant, while the dried products uses the aboveground parts, which are cleaned, selected and processed before use. Fresh products are harvested regardless of season, while dried products are harvested in both summer and autumn, with summer as the best. In ancient times, there were no specific requirements for the quality of HH, while in modern times, "intact stems and leaves with a strong fishy smell" are preferred. In addition, the medicinal properties of HH have undergone significant changes from ancient to modern times. In the early period, it was believed that its medicinal property was slightly warm, until the 1977 edition of Chinese Pharmacopoeia officially changed it to slightly cold. Both ancient and modern literature states that HH can be used for the treatment of carbuncle and malignant sores, Lyuchanyan Bencao for the first time introduced HH fresh juice can relieve summer heat, since Diannan Bencao recorded that it can be used for lung carbuncle, and gradually developed into the first choice for the treatment of lung carbuncle. Based on the research results, it is suggested that fresh herb or dried aboveground parts of H. cordata are used as medicine when developing famous classical formulas.
2.Mechanism of Kaixuan Jiedu Core Prescription in Regulating PTGS2 to Improve Skin Lesions in Psoriasis Mouse Models
Xue XIAO ; Liping KANG ; Dan DAI ; Yidi MA ; Bin YANG ; Ping SONG
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(17):49-59
ObjectiveTo identify the active constituents of Kaixuan Jiedu core prescription (KXJD) and investigate its effective components and therapeutic targets in the treatment of common psoriasis
3.Mechanism of Kaixuan Jiedu Core Prescription in Regulating PTGS2 to Improve Skin Lesions in Psoriasis Mouse Models
Xue XIAO ; Liping KANG ; Dan DAI ; Yidi MA ; Bin YANG ; Ping SONG
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(17):49-59
ObjectiveTo identify the active constituents of Kaixuan Jiedu core prescription (KXJD) and investigate its effective components and therapeutic targets in the treatment of common psoriasis
4.Formulation and modification of high-fat meals in food impact studies
Qian-Qian JIANG ; Wei ZHANG ; Xiao-Na XIANG ; Jun HUANG ; Bo JIANG ; Dan-Dan YANG
The Chinese Journal of Clinical Pharmacology 2024;40(2):273-275
The food effect(FE)on drug absorption is an important part of clinical pharmacological studies of new drugs.The caloric ratios for each component of a high-fat meal are specified in the"Technical Guidelines for Food Bioavailability and Postprandial Bioequivalence Studies"approved by the US Food and Drug Administration(FDA)and the"Technical Guidelines for Food Effect Studies in New Drug Development"approved by the National Medical Products Administration.However,the recipes for high-fat meals vary among clinical research centers,showing their advantages and disadvantages.Thus,we present a modified version of high-fat meal recipes with easy-to-quantify calories,which is a combination of Western and Chinese flavors,easy to prepare,and meets Chinese tastes.The center satisfaction surveys showed that our modified version of the high-fat meal recipe greatly improved subject satisfaction and compliance,thus better safeguarding the quality of the trial.
5.Analysis of the research status of AA-CYP-HETE/EETs metabolic pathways and cardiovascular disease therapeutic drugs
Ming-Xia HU ; Yong-Yun HE ; Yue YAO ; Xiao-Dan MO ; Xiu-Fen YANG
The Chinese Journal of Clinical Pharmacology 2024;40(4):619-623
20-hydroxyeicosatetraenoic acid(20-HETE)and epoxyeicosatrienoic acids(EETs)are products of enzyme metabolism of arachidonic acid(AA)by cytochrome P450(CYP).20-HETE is mainly produced by CYP4A,CYP4F metabolism of AA,which has a certain toxic effect on the cardiovascular and cerebrovascular system.EETS is mainly produced by CYP2J,CYP2C metabolizes AA,which has a certain protective effect on the cardiovascular and cerebrovascular system.This article reviews the effects and mechanisms of drugs related to AA-CYP-HETE/EETs metabolic pathway on cardiovascular diseases such as myocardial hypertrophy,hypertension,heart failure,and myocardial infarction,in order to provide a reference for the clinical use of cardiovascular diseases and provide ideas and directions for the basic research and development of cardiovascular disease treatment drugs.
6.Clinical trial of rituximab and leflunomide in the treatment of patients with systemic lupus erythematosus
Jia-Hui GUO ; Jun-Jie ZOU ; Yang-Yang WANG ; Jin-Long ZHANG ; Dan-Dan PANG ; Xiao-Yan XU
The Chinese Journal of Clinical Pharmacology 2024;40(11):1547-1550
Objective To observe the clinical efficacy and safety of rituximab injection combined with leflunomide tablets in the treatment of patients with systemic lupus erythematosus(SLE).Methods The SLE patients were divided into control and treatment groups according to cohort method.The control group received leflunomide with 50 mg·d-1 after meal in the first 3 days of treatment and was adjusted to 20 mg·d-1 thereafter.On the basis of control group,the treatment group was combined with rituximab,375 mg·m-2 was given intravenously every 2 weeks in the first 3 times of treatment,and adjusted to once every 4 weeks from the 4th dose.Two groups were treated for 24 weeks.The clinical efficacy,systemic lupus erythematosus disease activity index(SLEDAI)scores,serological indicators,24-hour urinary protein and adverse drug reactions were compared between two groups.Results The treatment and control groups were enrolled 74 cases and 72 cases,respectively.After treatment,the total effective rates of treatment and control groups were 91.89%(68 cases/74 cases)and 79.17%(57 cases/72 cases)with significant difference(P<0.05).After treatment,the SLEDAI scores of treatment and control groups were(7.21±1.67)and(9.03±1.35)points;the levels of anti-Smith/ribonucleoprotein antibodies were(81.43±18.25)and(59.38±14.61)U·mL-1;the levels of immunoglobulin G were(12.04±2.15)and(17.28±2.64)g·L-1;the levels of interleukin-10 were(33.39±7.13)and(39.87±9.02)pg·mL-1;24-hour urinary protein quantification were(1.46±0.32)and(2.67±0.54)g·24 h-1;all the differences were statistically significant(all P<0.05).The drug adverse reactions of two groups were liver and kidney function injury and digestive tract reactions.The total incidences of drug adverse reactions in the treatment and control groups were 13.51%and 5.56%without significant difference(P>0.05).Conclusion Rituximab injection combined with leflunomide tablets has a definitive clinical efficacy in the treatment of SLE patients,which can significantly reduce disease activity and inflammatory reactions,improve immune function,without increasing the incidence of drug adverse reactions.
7.Research on dynamic monitoring of drug consumption based on statistical process control
Yang CHEN ; Chonghui DAN ; Meiling XU ; Xiao CHEN ; Ying LIU ; Xiaoyuan ZHENG
China Pharmacy 2024;35(19):2328-2334
OBJECTIVE To investigate a method for dynamic monitoring of drug consumption (DMDC) based on statistical process control (SPC), aiming to improve the macro-supervisory capacity in the process of drug utilization. METHODS The lists of key monitoring drug varieties in our hospital were established based on drug cost and relevant national documents. Monthly consumption data of key monitoring drug varieties in the entire hospital, outpatient pharmacy and inpatient pharmacy were taken as monitoring objects,and the DMDC model was established using SPC’s X control chart, moving range control chart, and exponentially weighted moving-average control chart, monitoring from three dimensions: single-month consumption, range variation, and consumption trend. Rosuvastatin, metoprolol and meropenem were taken as examples to demonstrate the monitoring capabilities of the DMDC model. RESULTS Lists of key monitoring drug varieties were established for entire hospital, outpatient pharmacy and inpatient pharmacy, containing 203, 167 and 200 varieties, respectively. After excluding drug varieties that could not be modeled and for which modeling failed, 179, 116 and 172 DMDC models were successfully established for these three drug consumption areas, respectively. During the first four months of 2024, these three groups of model separately warned 54, 32 and 62 drug varieties. The DMDC model successfully monitored the monthly consumption of drugs,such as rosuvastatin throughout the hospital, metoprolol in outpatient pharmacy, and meropenem in inpatient pharmacy. Compared with the previously used floating rate ranking method in our hospital, the application of the DMDC model significantly improved the scope and depth of drug monitoring, with the monitored drug varieties greatly expanded from about 50 to 179, and the monitoring dimensions increased from a single dimension to three. CONCLUSIONS The DMDC model based on SPC is effective and feasible,suitable for monitoring drug varieties with stable monthly consumption.
8.SARS-CoV-2 antibody level one month after COVID-19 infection in healthcare workers in Pudong New Area of Shanghai
Shaohua GUO ; Xuelian FU ; Yaojun LYU ; Yifeng SHEN ; Xiao WANG ; Dan LIU ; Laibao YANG
Shanghai Journal of Preventive Medicine 2024;36(2):128-133
ObjectiveTo investigate the levels of serum antibodies against novel coronavirus (SARS-CoV-2) in healthcare workers after one month of natural infection, to explore the influencing factors and their correlations with the levels of antibodies, and to provide reference for strengthening the protection of healthcare workers and preventive intervention in Pudong New Area in Shanghai. MethodsVenous blood samples were collected from 1 102 medical staff in Pudong hospitals one month after infection. The serum levels of new coronavirus specific antibodies IgM, IgG and neutralizing antibodies were detected by chemiluminescent immunoassay. The information of gender, age, position, infection severity, vaccination, basic diseases and use of immunosuppressants were obtained by questionnaire to explore the influencing factors and their correlation with the antibody level. ResultsOne month after natural infection, 99.00% (1 091/1 102) of the subjects were found to be positive for IgG antibody against the new coronavirus, 17.79% (196/1 102) of the subjects were IgM antibody positive, and 99.00% (1 091/1 102) of the samples were positive for the neutralizing antibody. The level of antibody might be influenced by the severity of infection, the time of the last dose of vaccination, and the long-term use of immunosuppressants. The more severe the disease, the stronger the neutralizing antibody response. The antibody level in the people who received the final dose of vaccine within 6 months was higher than that of the people who received the vaccine 6 months ago, and the difference was statistically significant. The antibody levels were low in the subjects who received long-term immunosuppressants. ConclusionThe specific IgM, IgG and neutralizing antibody were found, one month after infection, in the medical workers in Pudong New Area, Shanghai, and the antibody titers were high, which had a good protective effect. The antibody level of the people who were vaccinated within 6 months was higher, it is recommended that people who receive the last vacination more than 6 months should be re-vaccinated with the booster vaccine, to improve the autoimmunity against the novel coronavirus.
9.Effects of Modified Xiaoyao Powder (逍遥散) on the Programmed Cell Death of Hypothalamic Dopaminergic Neurons in Rat Model of Hyperprolactinemia with Liver Depression and Spleen Deficiency
Yan LI ; Yan LI ; Kaixin LIU ; Kangli DAI ; Xiao LIU ; Hui YANG ; Dan LUO
Journal of Traditional Chinese Medicine 2024;65(3):317-323
ObjectiveTo investigate the possible mechanisms of modified Xiaoyao Powder (逍遥散) in the treatment of hyperprolactinemia (HPRL) with liver constraint and spleen deficiency. MethodsNinety-six female SD rats were randomly divided into a normal group (n=16) and a modeling group (n=80). In the modeling group, rats were subjected to chronic unpredictable stress combined with intraperitoneal injection of metoclopramide to establish a rat model of HPRL with liver constraint and spleen deficiency. The 80 successfully modeled rats were randomly divided into a model group, a high, medium, and low-dose group of modified Xiaoyao Powder, and a bromocriptine group, with 16 rats in each group. The high, medium, and low-dose groups of modified Xiaoyao Powder were orally administered doses of 60, 30, and 15 g/(kg·d) respectively, the bromocriptine group was orally administered bromocriptine tablets at a dose of 1 mg/(kg·d), and the normal group and model group were orally administered 10 ml/(kg·d) of normal saline for 14 consecutive days. ELISA was used to detect serum prolactin (PRL) level; immunohistochemistry was used to determine the expression of tumor necrosis factor-alpha (TNF-α) and tyrosine hydroxylase (TH) in the hypothalamus; Western blot was used to detect the protein expression of tumor necrosis factor receptor 1 (TNFR1) in the hypothalamus; Real-time PCR was used to detect the mRNA expression of receptor interacting protein kinase 3 (RIP3) in the hypothalamus; immunofluorescence was used to detect the co-expression of RIP3 and dopamine neurons in the hypothalamus. ResultsCompared with the normal group, the serum PRL levels were increased in the model group, and the expression of hypothalamic TNF-α, TNFR1, RIP3 mRNA, and the co-expression of RIP3 with dopamine neurons were significantly increased, while TH expression was decreased (P<0.05 or P<0.01). Compared with the model group, the expression of hypothalamic TNF-α was decreased in the bromocriptine group and low-dose group of modified Xiaoyao Powder, and the expression of TH was significantly increased in the medium and high-dose groups of modified Xiaoyao Powder and the bromocriptine group. The serum PRL levels, hypothalamic TNFR1 and RIP3 mRNA expression, and the co-expression of RIP3 with dopamine neurons were significantly decreased in all dose groups of modified Xiaoyao Powder and the bromocriptine group (P<0.05 or P<0.01). Compared with the bromocriptine group, the serum PRL level were significantly increased in the high and low-dose groups of modified Xiaoyao Powder, TH expression was significantly increased in the medium-dose group of modified Xiaoyao Powder, hypothalamic RIP3 mRNA expression was decreased in the low-dose group of modified Xiaoyao Powder, and the co-expression of RIP3 with dopamine neurons was significantly increased in the high-dose group of modified Xiaoyao Powder (P<0.01). ConclusionModified Xiaoyao Powder can regulate the programmed cell death of hypothalamic dopamine neurons, affect DA expression, and regulate PRL levels, which may be one of its mechanisms in the treatment of HPRL with liver constraint and spleen deficiency.
10.Herbal Textual Research on Curculiginis Rhizoma in Famous Classical Formulas
Jinfang LUO ; Yaoyao HUANG ; Tao ZHOU ; Yang YU ; Guoqiong CAO ; Dan ZHAO ; Chenhong XIAO ; Zhilai ZHAN
Chinese Journal of Experimental Traditional Medical Formulae 2024;30(14):199-208
By consulting the ancient and modern literature, the name, origin, quality evaluation, harvesting and processing methods of Curculiginis Rhizoma(CR) were systematically combed and verified, in order to provide a basis for the development and utilization of famous classical formulas containing CR. The results of herbal textual research showed that the name Xianmao was first recorded in Leigong Paozhilun, the name of CR was used in all dynasties and this name came from its efficacy and morphological characteristics, the mainstream source for CR of the past dynasties was the rhizome of Curculigo orchioides or C. capitulata, since modern times, C. orchioides has been the main source of commodities. In ancient times, most of the places of origin of the description were the western regions and southwest China, while in modern times, Sichuan and Guizhou were regarded as genuine places. Since modern times, its quality has been summarized as the best with thick roots, firm texture and black-brown surface, the harvesting and processing methods recorded in the past dynasties are mainly sun drying after harvest in the second, eighth and ninth months of the lunar calendar, and most of them are harvested in autumn and winter in modern times. In ancient times, there were many processing methods of CR, mainly in processing with rice swill, while in modern times, stir-frying with wine was the main processing method. The nature, taste, meridian tropism, functions and indications of CR are basically consistent from ancient to modern times, the taboos for taking are to avoid iron, cow's milk, and beef. Although there are some differences in the understanding of the toxicity of CR in the past dynasties, most of the materia medica are clear that it has a certain toxicity. Based on the research conclusion, it is suggested that the rhizome of C. orchioides of Lycoris family should be used as its source in the famous classical formulas, and the corresponding processing method should be selected according to the processing requirements in the formulas, while the raw products is recommended to be selected as medicine if the processing requirement is not specified.

Result Analysis
Print
Save
E-mail